W
WAVEMAN · COMPANY
KROS · Keros Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

KROS

Keros Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001664710
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$115.4K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
61
13F, latest reported quarter
REVENUE GROWTH
+6775.0%
XBRL, annual
NET MARGIN
35.7%
CONVERSIONS · 180D
1
codes C/M, not in net · $16.5K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$115.4K over 180 days
-$75.6K over 90 days
more than 55% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
61 funds added or opened last quarter
below 51% of Pharma & Biotech
REVENUE
+6775.0% year over year
more than 99% of Pharma & Biotech
MARGIN
35.7% net margin
more than 94% of Pharma & Biotech
BUYBACKS
$375.0M repurchased, FY to 2025-12-31
more than 85% of Pharma & Biotech
SHORT
5.0% of shares outstanding short · 5.9 days to cover · settled 2026-07-31
more than 54% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$115.4K across 7 people in 180 days.
61 funds added or opened positions in the latest 13F quarter, of 133 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -29.3%
-29.3%12M
-37%-12%+14%+39%2025-092025-102025-122026-032026-052026-072026-09 2025-10-15 · Schneeberger Daniel sold $77.9M2025-10-15 · Pontifax (China) IV L.P. sold $40.6M2025-10-15 · Pontifax (China) IV L.P. sold $21.8M2025-10-15 · Pontifax (China) IV L.P. sold $19.9M2025-10-15 · Schneeberger Daniel sold $13.2M2025-10-15 · Schneeberger Daniel sold $4.5M2025-10-15 · Pontifax (China) IV L.P. sold $2.8M2026-02-19 · Seehra Jasbir sold $113.4K2026-02-18 · Cho Esther sold $77.6K2026-02-18 · Regnante Keith sold $77.5K2026-02-18 · Lerner Lorena Raquel sold $63.3K2026-08-18 · Cho Esther sold $46.2K2026-08-18 · Lerner Lorena Raquel sold $36.7K2026-06-04 · Farzan Nima sold $28.2K2026-06-04 · Knowles Julius sold $28.2K2026-06-04 · Seth Alpna sold $28.1K2026-03-09 · BIENAIME JEAN JACQUES bought $22.4K2026-08-18 · Tanini Annita sold $12.6K2026-04-15 · BIENAIME JEAN JACQUES bought $11.7K2026-07-15 · BIENAIME JEAN JACQUES bought $10.6K2026-05-15 · BIENAIME JEAN JACQUES bought $10.6K2026-08-17 · BIENAIME JEAN JACQUES bought $10.3K2026-06-15 · BIENAIME JEAN JACQUES bought $10.2K2026-08-18 · Newton Charles W. sold $5.7K2026-06-11 · Newton Charles W. sold $5.5K2026-08-18 · Newton Charles W. filed to sell $5.7K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $115.4K sold by insiders over 180 days, 61 funds added last quarter, $5.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Keros Therapeutics, Inc. insiders sold a net $115.4K of stock across 172 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Lerner Lorena Raquel
Chief Scientific Officer
SELL
2026-08-18
3,568.0
$36.7K
Cho Esther
Chief Legal Officer
SELL
2026-08-18
4,485.0
$46.2K
Newton Charles W.
Director
SELL
2026-08-18
551.0
$5.7K
Tanini Annita
Corp. Controller & VP, Finance
SELL
2026-08-18
1,224.0
$12.6K
BIENAIME JEAN JACQUES
Director
BUY
2026-08-17
1,000.0
$10.3K
172 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 167 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Nantahala Capital Management, LLC
2,820,838.0 sh
$30.2M
BlackRock, Inc.
2,794,217.0 sh
$29.9M
AQR CAPITAL MANAGEMENT LLC
967,859.0 sh
$10.4M
VANGUARD CAPITAL MANAGEMENT LLC
833,596.0 sh
$8.9M
ORBIMED ADVISORS LLC
759,155.0 sh
$8.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Newton Charles W.
FILED 2026-08-18
$5.7K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Clinical Trials Etf
$142.7K POSITION · AS OF 2026-04-30
0.4%
OneAscent Enhanced Small and Mid Cap ETF
$204.7K POSITION · AS OF 2026-02-28
0.3%
AQR Small Cap Multi-Style Fund
$343.7K POSITION · AS OF 2026-03-31
0.2%
Federated Hermes MDT Small Cap Core Fund
$4.3M POSITION · AS OF 2026-04-30
0.2%
NVIT Small Cap Value Fund
$381.3K POSITION · AS OF 2026-03-31
0.2%
NVIT Multi-Manager Small Company Fund
$646.6K POSITION · AS OF 2026-03-31
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
3
Phase 2
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Jasbir Seehra
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$8.9M
$3.4M
$3.0M
-44%
-6%
2022
$6.5M
$710.1K
$3.3M
-32%
-10%
2021
$7.2M
-$4.5M
$2.9M
-17%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122025-102025-102024-12
REVENUE$244.1M——$3.5M
OPERATING INCOME$67.6M——$-210.8M
NET INCOME$87.0M——$-187.4M
EPS (DILUTED)2.30——-5.00
OPERATING CASH FLOW$107.5M——$-160.9M
CASH$287.4M——$559.9M
BUYBACKS$375.0M$194.4M$180.6M$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →